Anzeige
Mehr »
Login
Donnerstag, 14.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Kolumbiens nächster Kupferriese? Warum Investoren dieses 14.000-Meter-Bohrprogramm beobachten!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Actusnews Wire
440 Leser
Artikel bewerten:
(2)

QUANTUM GENOMICS: Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Faran

Finanznachrichten News

Quantum Genomics to receive up to $12.1 million in upfront and milestone payments plus double-digit royalties on sales

Faran to receive an exclusive license to develop and commercialize firibastat for the treatment of difficult to treat/resistant hypertension in Greece

Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult to treat/resistant hypertension today announced it has entered into an exclusive licensing and collaboration agreement with Faran to develop and commercialize firibastat in
Greece. This new agreement is the first step of Quantum Genomics' partnering strategy in Europe.

Under the terms of the agreement, Faran will receive exclusive commercialization rights to firibastat for the treatment of difficult to treat/resistant hypertension in Greece. Additionally, Faran may join the global study of difficult to treat/resistant hypertension in
Greece.

Quantum Genomics will receive upfront and milestone payments amounting up to $12.1 million, plus double-digit royalties on sales.

Over 20% of the adult general population in Greece suffers of Hypertension. Resistant hypertension is a common disorder with an estimated prevalence of more than 10% in the general hypertensive population.

"Faran who was established 70 years ago is one of the leading player in Greece. Having many long lasting partnerships with global pharmaceutical companies, Faran is focusing on eight innovative products and through an extented partnership with five more original products at Cardiology segment. We had intensive discussions with well experienced people and we are excited to partner firibastat with Faran in Greece », mentionned Jean-Philippe Milon, Chief Executive Officer of Quantum Genomics.

« Faran is investing and focusing on Cardiology, with a clear vision to become local market leader. We are very enthusiastic to establish partneship with Quantum Genomics» mentionned Mr Mario Katsikas, President & CEO of FARAN S.A..

About Faran
Faran is a Greek pharmaceutical company that aims to offer renowned High Quality therapeutic products, with High Therapeutic Value, Modern Pharmaceutical Technology and Documented Safety. To achieve this goal our horizons expanded daily with selected international partnerships and the trust of medical community by providing therapeutic solutions in a wide range of diseases in the area of Cardiology, Oncology, Haematology, Nephrology, Orthopaedics, Rheumatology, Endocrinology, International Medicine and Gynecology.
The people of Faran have in-depth knowledge of all the needs and specificities of the Greek Pharmaceutical Market and interested in health issues those concern citizens, healthcare professionals and insurance funds. They are qualitative and modern, direct and flexible.

About Quantum Genomics
Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on 20 years of academic research from the Paris-Descartes University and the laboratory directed by Dr. Catherine Llorens-Cortes at the Collège de France (French National Institute of Health and Medical Research (INSERM)/ the Scientific Centre for National Research (CNRS)). The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with severe heart failure dies within five years).
Based in Paris and New York, Quantum Genomics is listed on the Euronext Growth exchange in Paris (FR0011648971- ALQGC) and trades on the OTCQX Best Market in the United States (symbol: QNNTF).
For more information, please visit www.quantum-genomics.com, or follow us on Twitter and LinkedIn

Contacts

Quantum Genomics
Jean-Philippe Milon
CEO
jean-philippe.milon@quantum-genomics.com
Benoît Gueugnon
CFO
benoit.gueugnon@quantum-genomics.com
So Bang (Europe)
Nathalie Boumendil
Financial Communications
+33 (0)6 85 82 41 95 | nathalie@so-bang.fr
Samuel Beaupain
Media Relations and Scientific Communications
+33 (0)6 88 48 48 02 | samuel@so-bang.fr
LifeSci (USA)
Dan Ferry
Financial Communications
+1 (617) 535-7746 | Daniel@lifesciadvisors.com
Mike Tattory
Media Relations and Scientific Communications
+1 (609) 802-6265 | mtattory@lifescipublicrelations.com
------------------------
This publication embed "Actusnews SECURITY MASTER".
- SECURITY MASTER Key: x5lpYZlrZm+WlW1tkp5onJSXmJeTl2jIZ2HJxJZpapfIam1lnJyWZsaWZm9nmW5n
- Check this key: https://www.security-master-key.com.
------------------------
Full and original release in PDF format:
https://www.actusnews.com/documents_communiques/ACTUS-0-66491-quantum-genomics_faran-pr-english-version-final.pdf

© Copyright Actusnews Wire
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
© 2020 Actusnews Wire
Nach Nvidia: 5 KI-Revolutionäre aus der zweiten Reihe!
Künstliche Intelligenz hat spätestens nach dem Raketenstart von Chat GPT das Leben aller verändert. Doch der Superzyklus steht nach Meinungen von Experten erst am Anfang. Während Aktien wie Nvidia von der ersten Aufwärtsentwicklung stark profitieren konnten, versprechen aussichtsreiche Player aus der

zweiten Reihe noch enormes Aufwärtspotenzial.

Im kostenlosen, exklusiven Spezialreport präsentieren wir ihnen 5 innovative KI-Unternehmen, die bahnbrechende Entwicklungen in diesem Sektor prägen könnten.

Warum sollten Sie dabei sein?
Trotz der jüngsten Erfolge steht die Entwicklung der künstlichen Intelligenz noch am Beginn eines neuen Superzyklus. Experten gehen davon aus, dass der Sektor bis 2032 global auf 1,3 Billionen US-Dollar explodieren wird, wobei ein großer Teil auf Hardware und Infrastruktur entfallen wird.

Nutzen Sie die Chance!
Fordern Sie sofort unseren brandneuen Spezialreport an und erfahren Sie, welche 5 KI-Aktien das größte Potenzial zur Vervielfachung besitzen. Dieser Report ist komplett kostenlos und zeigt Ihnen die aussichtsreichsten Investments im KI-Sektor.
Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.